

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Results of a Phase III study evaluating CPX-351 versus conventional cytarabine/daunorubicin chemotherapy (7 + 3 regimen) demonstrated an improvement in which outcome with CPX-351 for older patients with secondary AML?
  - Complete response (CR) rate only
  - Overall survival only
  - Both CR rate and overall survival
- The FDA-approved FLT3 inhibitor gilteritinib is effective in patients with relapsed or refractory AML with which type of FLT3 mutation?
  - FLT3-TKD only
  - FLT3-ITD only
  - Both FLT3-TKD and FLT3-ITD
- Which of the following categories reflects the mechanism of action of blinatumomab?
  - Anti-PD-1/PD-L1 antibody
  - Bispecific T-cell engager
  - CAR T-cell therapy
  - IDH1/2 inhibitor
- The benefit of the antibody-drug conjugate gemtuzumab ozogamicin is greater for which subgroup of patients with CD33-positive AML?
  - Those with favorable risk
  - Those with poor risk
- Blinatumomab is currently FDA approved for adults and children with which subtype of ALL?
  - Minimal residual disease-positive
  - Treatment-naïve B-cell precursor
  - Both a and b
- Which of the following categories reflects the mechanism of action of APR-246?
  - Anti-PD-1/PD-L1 antibody
  - Bispecific T-cell engager
  - FLT3 inhibitor
  - Small molecule deactivator of mutated p53
- Which of the following statements is true regarding IDH mutations in AML?
  - The incidence of IDH1 mutations is markedly higher than the incidence of IDH2 mutations
  - The overall response rate with IDH inhibitors is about 40% for patients with IDH mutations
  - Both enasidenib and ivosidenib are active and FDA approved for patients with IDH1 mutations
- The recently FDA-approved CAR T-cell agent tisagenlecleucel is indicated for which of the following groups?
  - Patients up to 25 years of age with treatment-naïve disease
  - Patients up to 25 years of age with disease that is refractory to 1 prior line of therapy
  - Patients up to 25 years of age with disease that is refractory or in second or later relapse
- A Phase III trial (QUAZAR AML-001) presented at ASH 2019 demonstrated an overall survival benefit with which agent or regimen as maintenance therapy for patients with newly diagnosed AML in first remission?
  - APR-246
  - CPX-351
  - CC-486
  - Venetoclax/azacitidine
- Which of the following agents is a hedgehog inhibitor that is FDA approved for use in combination with low-dose cytarabine for the treatment of newly diagnosed AML in patients who are aged 75 or older or who have comorbidities that preclude intensive induction chemotherapy?
  - Gemtuzumab ozogamicin
  - Glasdegib
  - Ivosidenib
  - Gilteritinib